Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection

Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Medicines Agency’s ...